The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Proceeds from note payable, related parties | 0 |
| Payment on notes payable-Nonrelated Party | 0 |
| Payment on convertible note payable | 0 |
| Proceeds from offering, net of offering costs | 0 |
| Proceeds from sale of common stock | 0 |
| Payment on notes payable-Related Party | 146,432 |
| Proceeds from issuance convertible note payable, net | 5,580,000 |
| Net cash provided by financing activities | 5,433,568 |
| Loss on change in fair value of derivative liability | 0 |
| Amortization of debt discounts | 0 |
| Loss (gain) on extinguishment of debt | 0 |
| Gain on forgiveness of accrued compensation | 0 |
| Decrease (increase) in prepaid contracts | 0 |
| Increase in prepaid and other current assets | 0 |
| Amortization of prepaid contracts | 766,666 |
| Non-cash financing cost | 200,000 |
| Interest expense paid through sale of common stock | 22,521 |
| Stock-based compensation | 2,418,516 |
| Increase in accounts receivable | 2,637 |
| Increase in inventory | 159,790 |
| Increase in other current assets | -7,544 |
| Decrease in operating lease right of use asset | 3,654 |
| Increase in deferred revenue | 735 |
| Increase in accounts payable and accrued expenses | 242,163 |
| Decrease in accrued compensation | -17,736 |
| Increase in accrued interest | 38,765 |
| Gain on change in fair value of convertible notes | 281,932 |
| Net loss | -8,644,897 |
| Net cash used in operating activities | -5,413,736 |
| Net change in cash | 19,832 |
| Net change in cash | 19,832 |
| Beginning of period | 3,769,510 |
| End of period | 3,789,342 |
JUPITER NEUROSCIENCES, INC. (JUNS)
JUPITER NEUROSCIENCES, INC. (JUNS)